CBL0137 impairs homologous recombination repair and sensitizes high-grade serous ovarian carcinoma to PARP inhibitors
Xue Lu(Griffith University), Kum Kum Khanna(Queensland University of Technology), Michael Friedländer(Prince of Wales Hospital), Murugan Kalimutho(Griffith University), Devathri Nanayakarra(QIMR Berghofer Medical Research Institute), Sivanandhini Sankarasubramanian(QIMR Berghofer Medical Research Institute), J. Alejandro López(Griffith University), Rebecca L. Johnston(QIMR Berghofer Medical Research Institute), John D. Hooper(Millennium Institute for Integrative Biology), Yaowu He(Translational Research Institute), Prahlad V. Raninga(QIMR Berghofer Medical Research Institute)
Cited by 14
Related Papers
Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
|New England Journal of Medicine|2018|2.9k
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial
|The Lancet|2010|2.3k
Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial
|The Lancet Oncology|2017|1.9k
Olaparib Monotherapy in Patients With Advanced Cancer and a Germline <i>BRCA1/2</i> Mutation
|Journal of Clinical Oncology|2014|1.7k
Whole–genome characterization of chemoresistant ovarian cancer
|Nature|2015|1.7k